Gene variants affect response to antiepileptic drugs.
Senior
Kath
K
D017398:Alternative Splicing / Q000235:genetics; D000927:Anticonvulsants / Q000494:pharmacology*; D002220:Carbamazepine / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics*; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D005091:Exons / Q000235:genetics; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D062550:NAV1.1 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000235:genetics*; D010672:Phenytoin / Q000494:pharmacology; D011110:Polymorphism, Genetic / Q000235:genetics; D015222:Sodium Channels / Q000235:genetics*
D000927:Anticonvulsants; D062550:NAV1.1 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; C568242:SCN1A protein, human; D015222:Sodium Channels; C400322:cytochrome P-450 CYP2C subfamily; D002220:Carbamazepine; D010672:Phenytoin; D003577:Cytochrome P-450 Enzyme System